UniQure Aiming To Be First With Hemophilia B Gene Therapy
Presenting 12 Month Data At ASH
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
You may also be interested in...
The company plans to file with 52-week data for AMT-061 and is confident it won't face the same stringent requirements from the FDA that led to a complete response letter for BioMarin's Roctavian.
Syncona-backed Freeline has nabbed an "accomplished commercial leader" in Theresa Heggie to lead the company as it prepares to take FLT180a, its gene therapy for hemophilia B, into Phase III.
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.